 Rachel Friedman
Concepts (253)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| T-Lymphocytes | 18 | 2022 | 1774 | 3.300 |
Why?
| | Islets of Langerhans | 7 | 2022 | 739 | 2.310 |
Why?
| | Cell Movement | 9 | 2020 | 896 | 1.440 |
Why?
| | Autoimmunity | 8 | 2021 | 831 | 1.410 |
Why?
| | Antigen-Presenting Cells | 7 | 2021 | 156 | 1.310 |
Why?
| | Diabetes Mellitus, Type 1 | 11 | 2022 | 3360 | 1.290 |
Why?
| | CD8-Positive T-Lymphocytes | 7 | 2022 | 702 | 0.960 |
Why?
| | CD11c Antigen | 3 | 2019 | 38 | 0.940 |
Why?
| | Cell Communication | 5 | 2014 | 281 | 0.880 |
Why?
| | B-Lymphocytes, Regulatory | 1 | 2022 | 4 | 0.850 |
Why?
| | c-Mer Tyrosine Kinase | 1 | 2021 | 43 | 0.810 |
Why?
| | Phagocytes | 1 | 2021 | 91 | 0.780 |
Why?
| | Disasters | 1 | 2022 | 89 | 0.770 |
Why?
| | Autoantigens | 4 | 2018 | 397 | 0.720 |
Why?
| | Mice, Inbred NOD | 7 | 2022 | 574 | 0.700 |
Why?
| | Antigen Presentation | 7 | 2017 | 194 | 0.660 |
Why?
| | Stress, Physiological | 2 | 2022 | 415 | 0.660 |
Why?
| | Homeostasis | 1 | 2022 | 594 | 0.640 |
Why?
| | Lymphocyte Activation | 11 | 2022 | 1067 | 0.630 |
Why?
| | B-Lymphocytes | 4 | 2019 | 770 | 0.630 |
Why?
| | Diabetes Mellitus, Experimental | 2 | 2021 | 211 | 0.630 |
Why?
| | Dendritic Cells | 6 | 2018 | 442 | 0.610 |
Why?
| | Coronary Artery Disease | 1 | 2022 | 647 | 0.540 |
Why?
| | Cellular Microenvironment | 2 | 2014 | 79 | 0.500 |
Why?
| | Immunological Synapses | 2 | 2013 | 18 | 0.500 |
Why?
| | Signal Transduction | 6 | 2019 | 4709 | 0.480 |
Why?
| | Animals | 32 | 2022 | 33381 | 0.470 |
Why?
| | Diabetes Mellitus | 1 | 2022 | 942 | 0.470 |
Why?
| | Telemedicine | 1 | 2022 | 664 | 0.470 |
Why?
| | Lymph Nodes | 5 | 2018 | 455 | 0.460 |
Why?
| | Peripheral Tolerance | 1 | 2013 | 14 | 0.450 |
Why?
| | Receptors, Antigen, T-Cell | 3 | 2014 | 632 | 0.450 |
Why?
| | Hypertension | 1 | 2022 | 1203 | 0.450 |
Why?
| | Cancer Vaccines | 2 | 2004 | 139 | 0.440 |
Why?
| | Mice | 21 | 2022 | 15520 | 0.420 |
Why?
| | Cell Adhesion Molecules | 3 | 2022 | 180 | 0.400 |
Why?
| | Therapeutic Touch | 1 | 2010 | 3 | 0.390 |
Why?
| | CD4-Positive T-Lymphocytes | 6 | 2018 | 984 | 0.370 |
Why?
| | Mice, Inbred C57BL | 10 | 2022 | 4908 | 0.360 |
Why?
| | Antigens | 3 | 2021 | 320 | 0.340 |
Why?
| | Microfilament Proteins | 2 | 2022 | 134 | 0.340 |
Why?
| | Heart Failure | 1 | 2022 | 1969 | 0.340 |
Why?
| | Asthma | 1 | 2022 | 2158 | 0.330 |
Why?
| | Epitopes, T-Lymphocyte | 3 | 2004 | 170 | 0.330 |
Why?
| | Listeria monocytogenes | 2 | 2017 | 110 | 0.320 |
Why?
| | Mice, Knockout | 11 | 2020 | 2680 | 0.320 |
Why?
| | Phosphoproteins | 2 | 2022 | 308 | 0.310 |
Why?
| | Regeneration | 1 | 2009 | 165 | 0.310 |
Why?
| | Wound Healing | 1 | 2009 | 270 | 0.300 |
Why?
| | Mice, Transgenic | 6 | 2021 | 2025 | 0.300 |
Why?
| | Acute Coronary Syndrome | 1 | 2010 | 257 | 0.290 |
Why?
| | Chromogranin A | 2 | 2018 | 40 | 0.290 |
Why?
| | Heart Rate | 1 | 2010 | 729 | 0.290 |
Why?
| | Intracellular Fluid | 1 | 2005 | 26 | 0.270 |
Why?
| | Extracellular Fluid | 1 | 2005 | 32 | 0.270 |
Why?
| | Chemokines | 1 | 2006 | 230 | 0.260 |
Why?
| | Immune Tolerance | 2 | 2021 | 334 | 0.260 |
Why?
| | Microscopy, Fluorescence, Multiphoton | 3 | 2013 | 66 | 0.260 |
Why?
| | Stem Cells | 1 | 2009 | 559 | 0.250 |
Why?
| | High Mobility Group Proteins | 1 | 2004 | 50 | 0.240 |
Why?
| | Aging | 2 | 2015 | 1670 | 0.240 |
Why?
| | Epitopes | 1 | 2005 | 443 | 0.230 |
Why?
| | Biomedical Research | 1 | 2009 | 612 | 0.230 |
Why?
| | Nonmuscle Myosin Type IIA | 2 | 2014 | 8 | 0.220 |
Why?
| | Trans-Activators | 2 | 2009 | 373 | 0.220 |
Why?
| | Actins | 2 | 2022 | 404 | 0.210 |
Why?
| | Cell Adhesion | 4 | 2017 | 443 | 0.210 |
Why?
| | CD11 Antigens | 1 | 2021 | 32 | 0.200 |
Why?
| | Recombination, Genetic | 2 | 2018 | 173 | 0.200 |
Why?
| | HIV Antigens | 1 | 2000 | 17 | 0.190 |
Why?
| | Neoplasms, Experimental | 1 | 2021 | 158 | 0.190 |
Why?
| | Conservation of Natural Resources | 1 | 2021 | 107 | 0.190 |
Why?
| | Airway Remodeling | 1 | 2020 | 57 | 0.180 |
Why?
| | Humans | 20 | 2022 | 118974 | 0.180 |
Why?
| | Adenine | 1 | 2021 | 223 | 0.180 |
Why?
| | Immune System | 2 | 2013 | 181 | 0.180 |
Why?
| | Wnt Proteins | 1 | 2020 | 140 | 0.170 |
Why?
| | Piperazines | 1 | 2021 | 316 | 0.170 |
Why?
| | Wnt Signaling Pathway | 1 | 2020 | 150 | 0.170 |
Why?
| | Myeloid Cells | 1 | 2019 | 128 | 0.160 |
Why?
| | Neovascularization, Pathologic | 1 | 2020 | 287 | 0.160 |
Why?
| | Ambulatory Care | 1 | 2022 | 482 | 0.160 |
Why?
| | Endothelial Cells | 3 | 2020 | 732 | 0.160 |
Why?
| | Islet Amyloid Polypeptide | 1 | 2018 | 47 | 0.160 |
Why?
| | Membrane Proteins | 1 | 2004 | 1055 | 0.160 |
Why?
| | C-Peptide | 1 | 2018 | 137 | 0.150 |
Why?
| | Molecular Imaging | 1 | 2018 | 54 | 0.150 |
Why?
| | Receptors, Interferon | 1 | 2017 | 49 | 0.150 |
Why?
| | Hospitals | 1 | 2022 | 598 | 0.150 |
Why?
| | Transendothelial and Transepithelial Migration | 1 | 2017 | 27 | 0.150 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 2018 | 130 | 0.150 |
Why?
| | Interleukin-4 | 1 | 2018 | 215 | 0.150 |
Why?
| | Cells, Cultured | 4 | 2018 | 4077 | 0.150 |
Why?
| | Listeriosis | 1 | 2017 | 60 | 0.150 |
Why?
| | Prostatic Neoplasms | 1 | 2004 | 940 | 0.140 |
Why?
| | Ecosystem | 1 | 2021 | 555 | 0.140 |
Why?
| | Spleen | 2 | 2015 | 510 | 0.130 |
Why?
| | Disease Progression | 2 | 2019 | 2490 | 0.130 |
Why?
| | Flow Cytometry | 4 | 2015 | 1085 | 0.130 |
Why?
| | HIV-1 | 1 | 2000 | 776 | 0.130 |
Why?
| | Female | 12 | 2021 | 61565 | 0.120 |
Why?
| | Phenotype | 1 | 2022 | 3003 | 0.120 |
Why?
| | Endothelium, Vascular | 1 | 2020 | 907 | 0.120 |
Why?
| | Inflammation | 3 | 2020 | 2566 | 0.110 |
Why?
| | Peptide Fragments | 3 | 2018 | 702 | 0.110 |
Why?
| | Alum Compounds | 1 | 2013 | 22 | 0.110 |
Why?
| | Encephalomyelitis, Autoimmune, Experimental | 1 | 2013 | 50 | 0.110 |
Why?
| | Gene Expression | 1 | 2018 | 1489 | 0.110 |
Why?
| | Chemokine CCL21 | 2 | 2015 | 13 | 0.110 |
Why?
| | Receptors, CCR7 | 2 | 2015 | 24 | 0.110 |
Why?
| | Internship and Residency | 1 | 2022 | 1001 | 0.110 |
Why?
| | Adjuvants, Immunologic | 1 | 2013 | 207 | 0.100 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2013 | 355 | 0.100 |
Why?
| | Autoimmune Diseases | 2 | 2018 | 398 | 0.100 |
Why?
| | Emergency Service, Hospital | 1 | 2022 | 1865 | 0.100 |
Why?
| | Lung Neoplasms | 1 | 2004 | 2220 | 0.100 |
Why?
| | Immunity, Cellular | 1 | 2013 | 270 | 0.100 |
Why?
| | Interferon-gamma | 1 | 2014 | 736 | 0.100 |
Why?
| | Music Therapy | 1 | 2010 | 21 | 0.090 |
Why?
| | Electrocardiography, Ambulatory | 1 | 2010 | 53 | 0.090 |
Why?
| | Lymphocyte Function-Associated Antigen-1 | 2 | 2008 | 35 | 0.090 |
Why?
| | Fluorescence | 1 | 2010 | 159 | 0.090 |
Why?
| | Macrophages | 1 | 2017 | 1324 | 0.090 |
Why?
| | Amino Acid Sequence | 3 | 2004 | 2071 | 0.090 |
Why?
| | Cell Transplantation | 1 | 2009 | 39 | 0.090 |
Why?
| | Molecular Sequence Data | 3 | 2004 | 2871 | 0.090 |
Why?
| | Obesity | 1 | 2022 | 2746 | 0.080 |
Why?
| | Self Tolerance | 1 | 2008 | 28 | 0.080 |
Why?
| | Stem Cell Transplantation | 1 | 2009 | 153 | 0.080 |
Why?
| | Lymphoid Tissue | 1 | 2008 | 65 | 0.080 |
Why?
| | Hepatocytes | 1 | 2009 | 205 | 0.080 |
Why?
| | Bone Marrow Transplantation | 1 | 2009 | 244 | 0.080 |
Why?
| | Paracrine Communication | 1 | 2008 | 57 | 0.080 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2022 | 2174 | 0.080 |
Why?
| | Lung | 1 | 2020 | 3664 | 0.080 |
Why?
| | Interleukin-2 | 1 | 2008 | 416 | 0.070 |
Why?
| | Cell Differentiation | 2 | 2018 | 1753 | 0.070 |
Why?
| | Cell Line, Tumor | 2 | 2004 | 2851 | 0.070 |
Why?
| | Cell Line, Transformed | 2 | 2004 | 136 | 0.070 |
Why?
| | Chemokines, CC | 1 | 2006 | 30 | 0.070 |
Why?
| | Receptors, Chemokine | 1 | 2006 | 45 | 0.070 |
Why?
| | Mice, Mutant Strains | 1 | 2006 | 280 | 0.070 |
Why?
| | DNA | 1 | 2013 | 1388 | 0.070 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2006 | 175 | 0.070 |
Why?
| | Mice, Inbred Strains | 1 | 2006 | 405 | 0.070 |
Why?
| | Emotions | 1 | 2010 | 495 | 0.070 |
Why?
| | Mice, Inbred BALB C | 3 | 2015 | 1206 | 0.060 |
Why?
| | Ligands | 1 | 2006 | 567 | 0.060 |
Why?
| | Cell Line | 2 | 2020 | 2707 | 0.060 |
Why?
| | SOXC Transcription Factors | 1 | 2004 | 5 | 0.060 |
Why?
| | Antibodies, Neoplasm | 1 | 2004 | 30 | 0.060 |
Why?
| | Leukocytes, Mononuclear | 2 | 2004 | 509 | 0.060 |
Why?
| | Antigens, CD | 1 | 2006 | 460 | 0.060 |
Why?
| | COS Cells | 1 | 2004 | 184 | 0.060 |
Why?
| | Antibody Specificity | 1 | 2004 | 184 | 0.060 |
Why?
| | Carcinoma, Small Cell | 1 | 2004 | 158 | 0.060 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2004 | 180 | 0.060 |
Why?
| | Recombinant Proteins | 3 | 2002 | 1308 | 0.060 |
Why?
| | Male | 8 | 2020 | 57801 | 0.060 |
Why?
| | Kallikreins | 1 | 2002 | 33 | 0.050 |
Why?
| | Clone Cells | 2 | 2018 | 248 | 0.050 |
Why?
| | Adoptive Transfer | 2 | 2015 | 204 | 0.050 |
Why?
| | Accreditation | 1 | 2022 | 87 | 0.050 |
Why?
| | Transfection | 1 | 2004 | 888 | 0.050 |
Why?
| | Polymerization | 1 | 2022 | 129 | 0.050 |
Why?
| | Cytoskeletal Proteins | 1 | 2022 | 146 | 0.050 |
Why?
| | Prostate-Specific Antigen | 1 | 2002 | 156 | 0.050 |
Why?
| | Hospitalization | 1 | 2010 | 1785 | 0.050 |
Why?
| | Listeria | 1 | 2000 | 6 | 0.050 |
Why?
| | Gene Products, nef | 1 | 2000 | 13 | 0.050 |
Why?
| | nef Gene Products, Human Immunodeficiency Virus | 1 | 2000 | 20 | 0.050 |
Why?
| | Polymerase Chain Reaction | 1 | 2004 | 1012 | 0.050 |
Why?
| | Neoplasm Proteins | 1 | 2004 | 401 | 0.050 |
Why?
| | Gene Products, gag | 1 | 2000 | 38 | 0.050 |
Why?
| | Lymphatic System | 1 | 2020 | 13 | 0.050 |
Why?
| | AIDS Vaccines | 1 | 2000 | 44 | 0.050 |
Why?
| | Alanine | 1 | 2000 | 102 | 0.050 |
Why?
| | Transcription Factors | 1 | 2008 | 1570 | 0.050 |
Why?
| | Genetic Vectors | 1 | 2000 | 302 | 0.040 |
Why?
| | Faculty, Medical | 1 | 2022 | 252 | 0.040 |
Why?
| | Vascular System Injuries | 1 | 2020 | 70 | 0.040 |
Why?
| | Specific Pathogen-Free Organisms | 1 | 2018 | 61 | 0.040 |
Why?
| | Sex Factors | 1 | 2004 | 1781 | 0.040 |
Why?
| | beta Catenin | 1 | 2020 | 219 | 0.040 |
Why?
| | Crosses, Genetic | 1 | 2018 | 138 | 0.040 |
Why?
| | Cytotoxicity, Immunologic | 1 | 1998 | 204 | 0.040 |
Why?
| | Education, Medical, Graduate | 1 | 2022 | 399 | 0.040 |
Why?
| | Germinal Center | 1 | 2018 | 47 | 0.040 |
Why?
| | Mice, 129 Strain | 1 | 2017 | 75 | 0.040 |
Why?
| | Basic-Leucine Zipper Transcription Factors | 1 | 2017 | 40 | 0.040 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 1998 | 158 | 0.040 |
Why?
| | Heat-Shock Proteins | 1 | 1998 | 129 | 0.040 |
Why?
| | Monocytes | 1 | 2000 | 513 | 0.040 |
Why?
| | Mice, SCID | 1 | 2018 | 333 | 0.040 |
Why?
| | Integrin alpha4 | 1 | 2017 | 7 | 0.040 |
Why?
| | Genes, Reporter | 1 | 2018 | 270 | 0.040 |
Why?
| | Pulmonary Emphysema | 1 | 2020 | 327 | 0.040 |
Why?
| | Microscopy | 1 | 2018 | 125 | 0.040 |
Why?
| | Chemotaxis | 1 | 2017 | 137 | 0.040 |
Why?
| | Interferon Type I | 1 | 2017 | 129 | 0.040 |
Why?
| | Macrophage Activation | 1 | 2017 | 168 | 0.030 |
Why?
| | Middle Aged | 2 | 2020 | 27617 | 0.030 |
Why?
| | Chemokine CCL19 | 1 | 2015 | 6 | 0.030 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2004 | 968 | 0.030 |
Why?
| | Curriculum | 1 | 2022 | 910 | 0.030 |
Why?
| | Microsatellite Repeats | 1 | 2015 | 143 | 0.030 |
Why?
| | Clinical Competence | 1 | 2022 | 951 | 0.030 |
Why?
| | Repressor Proteins | 1 | 2017 | 377 | 0.030 |
Why?
| | Down-Regulation | 1 | 2017 | 627 | 0.030 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2018 | 709 | 0.030 |
Why?
| | Software | 1 | 2018 | 613 | 0.030 |
Why?
| | Receptor Cross-Talk | 1 | 2013 | 22 | 0.030 |
Why?
| | Gene Expression Regulation | 2 | 2015 | 2445 | 0.030 |
Why?
| | Cytokinesis | 1 | 2013 | 46 | 0.030 |
Why?
| | Mice, Nude | 1 | 2013 | 663 | 0.020 |
Why?
| | Cell Fractionation | 2 | 2002 | 53 | 0.020 |
Why?
| | Lymphopenia | 1 | 2010 | 48 | 0.020 |
Why?
| | Phosphorylation | 1 | 2014 | 1633 | 0.020 |
Why?
| | Immune System Phenomena | 1 | 2009 | 2 | 0.020 |
Why?
| | Glucose-6-Phosphatase | 1 | 2008 | 32 | 0.020 |
Why?
| | Tumor Cells, Cultured | 2 | 2002 | 874 | 0.020 |
Why?
| | STAT5 Transcription Factor | 1 | 2008 | 43 | 0.020 |
Why?
| | Stromal Cells | 1 | 2008 | 102 | 0.020 |
Why?
| | Immunophenotyping | 1 | 2009 | 278 | 0.020 |
Why?
| | Biomarkers | 1 | 2018 | 3588 | 0.020 |
Why?
| | Autoantibodies | 1 | 2015 | 1335 | 0.020 |
Why?
| | Thymus Gland | 1 | 2008 | 300 | 0.020 |
Why?
| | Green Fluorescent Proteins | 1 | 2009 | 395 | 0.020 |
Why?
| | HIV Infections | 1 | 2000 | 2459 | 0.020 |
Why?
| | Homeodomain Proteins | 1 | 2009 | 468 | 0.020 |
Why?
| | Young Adult | 1 | 2020 | 10793 | 0.020 |
Why?
| | Epithelial Cells | 1 | 2008 | 963 | 0.010 |
Why?
| | HLA-D Antigens | 1 | 2002 | 36 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 2008 | 1323 | 0.010 |
Why?
| | Proteins | 1 | 2008 | 938 | 0.010 |
Why?
| | Hybridomas | 1 | 2002 | 233 | 0.010 |
Why?
| | Aged | 1 | 2020 | 19657 | 0.010 |
Why?
| | Conserved Sequence | 1 | 2002 | 219 | 0.010 |
Why?
| | Multigene Family | 1 | 2002 | 200 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2008 | 2275 | 0.010 |
Why?
| | Leukemia, Erythroblastic, Acute | 1 | 1998 | 9 | 0.010 |
Why?
| | Chemical Precipitation | 1 | 1998 | 38 | 0.010 |
Why?
| | Adult | 1 | 2020 | 31512 | 0.010 |
Why?
| | Granzymes | 1 | 1998 | 40 | 0.010 |
Why?
| | Serine Endopeptidases | 1 | 1998 | 105 | 0.010 |
Why?
| | Substrate Specificity | 1 | 1998 | 371 | 0.010 |
Why?
| | Cytoplasm | 1 | 1998 | 269 | 0.010 |
Why?
| | Cell Death | 1 | 1998 | 339 | 0.010 |
Why?
| | Immunity, Innate | 1 | 2002 | 745 | 0.010 |
Why?
| | Enzyme Activation | 1 | 1998 | 828 | 0.010 |
Why?
| | Hot Temperature | 1 | 1998 | 334 | 0.010 |
Why?
| | Protein Binding | 1 | 1998 | 1975 | 0.010 |
Why?
| | Time Factors | 1 | 1998 | 6412 | 0.000 |
Why?
|
|
Friedman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|